ArticleF&S reports2026
Evaluating concordance of preimplantation genetic testing-whole-genome sequencing with genetic findings in live-born children.
Article in F&S reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To clinically assess concordance between preimplantation genetic testing-whole-genome sequencing (PGT-WGS) and whole-genome sequencing results from corresponding live-born children, including evaluation of genome-wide variants, targeted gene panels, de novo variants, and genetic risk scores. Design: Patients underwent a standard in vitro fertilization workflow with PGT-WGS. After pregnancy or live birth, patients were contacted for consent to participate in this study. This small study included 10 biopsy-child pairs. Deoxyribonucleic acid (DNA) samples were collected from children, and whole-genome sequencing was performed accordingly. Genetic findings from PGT-WGS were compared with the child's whole-genome sequencing results. For de novo variant assessment (3 biopsy-child pairs), parental samples were also requested. Subjects: Clinical trophectoderm biopsy samples, corresponding live-born children, and parental DNA samples. Exposure: No applicable. Main Outcome Measures: Variant concordance across the whole genome and within designated gene panels; concordance of clinically relevant variants and de novo variants; concordance of functionally significant single-nucleotide polymorphisms (SNPs), including Results: Analysis of single-nucleotide variants (SNVs) and insertions/deletions (indels) identified an average of 3,562,534 variants genome-wide and 2,656 variants within the 1,200-gene panel per embryo-child pair, yielding a sensitivity of 97.6% and a precision of 98.4% on genome and 98.4% and 98.7% respectively, on monogenic panels.Traditional PGT approaches do not enable prospective screening for de novo variants. In this study, all 42 confirmed de novo variants detected in live-born children were also identified in the corresponding PGT-WGS results. High concordance (>99%) was observed on Conclusion: This study provides a small clinical study comparing PGT-WGS results with whole-genome sequencing findings in live-born children. Preimplantation genetic testing-whole-genome sequencing, offered using an opt-in panel of approximately 1,200 genes, demonstrated high sensitivity and precision and enabled direct interrogation of the trophectoderm genome. It has the feasibility to identify de novo variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.